Latest news with #TROPIONLung02
Medscape
14 hours ago
- Health
- Medscape
Updates in Metastatic NSCLC From ASCO 2025
Dr Jonathan Goldman, of the University of California, Los Angeles, shares key updates in metastatic non-small cell lung cancer from ASCO 2025. Dr Goldman reviews findings from TROPION-Lung02, which evaluated datopotamab deruxtecan (Dato-DXd) ± pembrolizumab (pembro) in first-line metastatic NSCLC. The objective response rate (ORR) was 55% for Dato-DXd + pembro vs 56% for chemo. Improved outcomes in TROP2 NMR-positive patients may indicate a predictive biomarker. Dr Goldman then discusses results from OptiTROP-Lung03, in which sacituzumab tirumotecan (sac-TMT) showed superior efficacy compared to docetaxel in pretreated EGFR-mutated NSCLC. The ORR for sac-TMT was 45% vs 15% for docetaxel. Next, he highlights updates from KRYSTAL-7 of first-line adagrasib plus pembro in KRASG12C-mutant NSCLC. The combination yielded an ORR of 44% and median duration of response of 26.3 months. In patients with a PD-L1 ≥ 50%, ORR reached 50% vs 34% in those with lower expression. Dr Goldman also reports on HERTHENA-Lung02, in which patritumab deruxtecan (HER3-DXd) improved progression-free survival (PFS) vs chemo in resistant EGFR-mutated NSCLC, but the lack of overall survival benefit led to application withdrawal. Finally, Dr Goldman reviews phase 2b findings from REZILIENT1, evaluating zipalertinib in EGFR exon 20-mutant NSCLC. In patients without prior amivantamab, ORR was 40% and PFS was 9.5 months. In those previously treated with amivantamab, zipalertinib resulted in clinically meaningful results: an ORR of 23.5% and PFS of 7.3 months.
Medscape
19-05-2025
- Health
- Medscape
Conference MDAngle: ASCO 2025 Advanced NSCLC
Preconference Considerations ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC Dr Preeshagul notes how excitement is building around new therapies for advanced NSCLC at ASCO 2025, especially for KRAS G12C, EGFR exon 20 insertions, and HER2 alterations, with several promising studies such as LOXO-RAS-20001 and zipalertinib monotherapy drawing attention. Emerging HER2-targeted small molecules such as zongertinib and BAY 2927088 are also being closely watched for their potential central nervous system activity. Additionally, antibody-drug conjugates such as those in the TROPION-Lung02 trial are generating interest for their potential roles across treatment lines. Quick Clinical Takeaways Coming soon: Dr Preeshagul highlights new data and progress regarding advanced NSCLC immediately following ASCO. How Will My Patients Benefit? Coming soon: Reflections from Dr Preeshagul on how new data from ASCO will affect her patients with advanced NSCLC. Image 1: Memorial Sloan Kettering Cancer Center
